Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168471 | 0.90 | USP2 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8242595 | 0.89 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL20511855 | 0.89 | USP2 (0.46) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL20873847 | 0.86 | USP2 (0.53) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL5637543 | 0.85 | MEN1 (0.48) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL23269711 | 0.84 | USP2 (0.56) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL2616174 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL15474971 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL39756 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8253901 | 0.84 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459451-A | Phenyl urea compound and preparation method and application thereof | 四川大学 | 2024-08-09 | — | — | CN | claimed |
| CN-117447424-A | Preparation method of 1-Boc-4- (2-chloroethyl) piperazine | 安徽昊帆生物有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4746882-A1 | INHIBITORS OF SMNDC1 AND THEIR THERAPEUTIC USE | CeMM - Forschungszentrum für Molekulare Medizin GmbH (AT) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006107923-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| CN-1245500-A | Novel naphthyridine derivatives | SUMITOMO PHARMA (JP) | 2000-02-23 | — | — | CN | disclosed |
| EP-0947515-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5843957-A | Naphthyridine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1998-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | USP2 3074/4885SMN1; SMN2 3985/4885CHRM2 862/4885 |
| US-20260144788-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | PTPN6, PTPN1, PTPN11 | USP2 762/4885SMN1; SMN2 2201/4885CHRM2 4793/4885 |
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | IL4I1, NFKBIA, BRD4 | USP2 3606/4885SMN1; SMN2 3411/4885CHRM2 4647/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | USP2 100/4885SMN1; SMN2 1087/4885CHRM2 2913/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | USP2 35/4885SMN1; SMN2 306/4885CHRM2 1490/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | USP2 181/4885SMN1; SMN2 2342/4885CHRM2 3356/4885 |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | USP2 4807/4885SMN1; SMN2 4492/4885CHRM2 190/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | USP2 87/4885SMN1; SMN2 3771/4885CHRM2 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.